These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24837538)

  • 1. Mind the gaps: what's missing from current economic evaluations of universal HPV vaccination?
    Marsh K; Chapman R; Baggaley RF; Largeron N; Bresse X
    Vaccine; 2014 Jun; 32(30):3732-9. PubMed ID: 24837538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
    Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
    Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
    Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.
    Isidean SD; Tota JE; Gagnon JA; Franco EL
    Expert Rev Vaccines; 2015 Jan; 14(1):119-33. PubMed ID: 25266065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
    de Kok IM; Habbema JD; van Rosmalen J; van Ballegooijen M
    Eur J Cancer; 2011 Feb; 47(3):428-35. PubMed ID: 20971633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ecological validity of cost-effectiveness models of universal HPV vaccination: A systematic literature review.
    Favato G; Easton T; Vecchiato R; Noikokyris E
    Vaccine; 2017 May; 35(20):2622-2632. PubMed ID: 28408119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries.
    Kostaras D; Karampli E; Athanasakis K
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):147-158. PubMed ID: 30501434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
    Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018.
    Jit M
    Value Health; 2021 Jan; 24(1):61-66. PubMed ID: 33431154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus vaccine and men: what are the obstacles and challenges?
    Stupiansky NW; Alexander AB; Zimet GD
    Curr Opin Infect Dis; 2012 Feb; 25(1):86-91. PubMed ID: 22143118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis.
    Bresse X; Goergen C; Prager B; Joura E
    Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):269-81. PubMed ID: 24450951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies.
    Ryser MD; McGoff K; Herzog DP; Sivakoff DJ; Myers ER
    Epidemics; 2015 Jun; 11():32-47. PubMed ID: 25979280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.